Une nouvelle étude a identifié une cible possible pour le traitement de la leucémie myélomonocytaire juvénile, un cancer du sang très agressif.
La recherche sur un type de cancer du sang appelé leucémie myélomonocytaire juvénile suggère un traitement anti-inflammatoire comme nouvelle thérapie possible de la maladie.
La leucémie myélomonocytaire juvénile (LMJ) est plus fréquente chez les enfants de moins de quatre ans. 10 % de tous les cas surviennent chez les nouveau-nés de moins de trois mois. Chaque année, un à deux enfants sur un million reçoivent un diagnostic de LMJM. La maladie représente environ 1,6 % de tous les cancers liés au sang. Elle est plus fréquente chez les garçons, les garçons étant presque deux fois plus susceptibles que les filles de développer un LMJM.
Les causes sous-jacentes exactes du LMJM ne sont pas claires, cependant, pratiquement tous les patients auront une mutation dans un gène RAS ou un gène qui affecte les niveaux d’activation des protéines Ras qui modifient le DNA within their blood cells. Currently, allogeneic hematopoietic stem cell transplantation is the only successful treatment for the majority of patients, although recent advancements show promise.
According to a report published on May 10th, 2022, in the journal eLife, scientists have identified a potential new target for treating patients with the blood cancer juvenile myelomonocytic leukemia (JMML).
Their findings in zebrafish and JMML patients suggest that anti-inflammatories may be a new approach to fighting the disease.
JMML is a highly aggressive blood cancer with poor patient outcomes. Children with Noonan Disease (NS), a relatively common developmental syndrome, are at a high risk of having a disorder similar to JMML called myeloproliferative neoplasm, which may later progress to JMML. A mutation in the PTPN11 gene, which encodes the protein-tyrosine phosphatase SHP2, is the most common genetic cause of JMML and NS.
“Hematopoietic stem and progenitor cells are considered to be the cells of origin for JMML,” says first author Maja Solman, Postdoctoral Fellow at the Hubrecht Institute, Utrecht, Netherlands. “Currently, hematopoietic stem cell transplantation is the only treatment for the disease, but it has a relapse rate of 50%. With such limited treatment options for JMML, we wanted to gain a better understanding of how the disease develops to identify other possible ways of targeting it.”
This image shows the macrophages (red) and neutrophils (green) in a zebrafish embryo with a mutation in SHP2. The head of the embryo is on the left, the tail on the right. Similar to the situation in JMML patients, this fish has more macrophages and neutrophils compared to fish without a mutation in SHP2. Credit: Maja Solman
To do this, Solman and the team used a novel zebrafish model with a mutation in SHP2 – equivalent to the most common mutation in NS patients which can cause JMML. They used a technique called single-cell transcriptomics to examine the level of gene expression in the animals’ hematopoietic stem and progenitor cells. The analysis showed an increase in the number of monocyte and macrophage progenitor cells in the fish embryos, and that these cells expressed genes associated with the immune response.
The team next compared these results with their analysis of hematopoietic stem and progenitor cells, which contained SHP2 mutations, from the bone marrow of JMML patients. They found a similar pattern of proinflammatory gene expression in these cells to the one they identified in the zebrafish.
Finally, they treated the zebrafish embryos with an anti-inflammatory drug called dexamethasone. They found that the drug helped rescue JMML-like blood defects in the fish, suggesting that anti-inflammatories could one day be an important treatment strategy for JMML.
“Our work reveals striking similarities in the proinflammatory response of human and zebrafish cells containing SHP2 mutations, and shows that inhibiting this response can improve JMML-like symptoms in a zebrafish model,” concludes senior author Jeroen den Hertog, Group Leader and Managing Director at the Hubrecht Institute, and Professor of Molecular Developmental Zoology at Leiden University, Netherlands. “Together, these findings lay the groundwork for future studies to verify the effectiveness of anti-inflammatories as a potential new treatment approach for JMML patients.”
Reference: “Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects” by Maja Solman, Sasja Blokzijl-Franke, Florian Piques, Chuan Yan, Qiqi Yang, Marion Strullu, Sarah M Kamel, Pakize Ak, Jeroen Bakkers, David M Langenau, Hélène Cavé and Jeroen den Hertog, 10 May 2022, eLife.
DOI: 10.7554/eLife.73040